• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach.不可切除的肝细胞癌：经动脉化疗栓塞联合乐伐替尼并联合程序性死亡-1抑制是一种可行的方法。
World J Gastrointest Oncol. 2024 Oct 15;16(10):4042-4044. doi: 10.4251/wjgo.v16.i10.4042.
2
Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.经动脉化疗栓塞联合 PD-1 抑制剂加仑伐替尼治疗不可切除肝细胞癌的疗效优于 PD-1 抑制剂加仑伐替尼。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231166765. doi: 10.1177/15330338231166765.
3
Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.索拉非尼、仑伐替尼或仑伐替尼联合 PD-1 抑制剂联合 TACE 治疗不可切除肝细胞癌：回顾性分析。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221133640. doi: 10.1177/15330338221133640.
4
The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.经动脉化疗栓塞/肝动脉灌注化疗联合乐伐替尼及PD-1抑制剂治疗门静脉癌栓型肝细胞癌的疗效：一项系统评价
Front Oncol. 2023 Mar 9;13:1054072. doi: 10.3389/fonc.2023.1054072. eCollection 2023.
5
Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis.经动脉化疗栓塞联合乐伐替尼加PD - 1抑制剂与经动脉化疗栓塞联合乐伐替尼治疗不可切除肝细胞癌的疗效和安全性：一项荟萃分析。
Front Immunol. 2024 Aug 30;15:1466113. doi: 10.3389/fimmu.2024.1466113. eCollection 2024.
6
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.不可切除肝细胞癌中仑伐替尼联合经动脉化疗栓塞术与程序性死亡受体-1 抑制剂联合或不联合的临床结局。
World J Gastroenterol. 2023 Mar 14;29(10):1614-1626. doi: 10.3748/wjg.v29.i10.1614.
7
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.经动脉化疗栓塞联合乐伐替尼加程序性细胞死亡蛋白-1抑制治疗不可切除肝细胞癌的疗效及预测因素
World J Gastrointest Oncol. 2024 Apr 15;16(4):1236-1247. doi: 10.4251/wjgo.v16.i4.1236.
8
Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.经动脉化疗栓塞联合乐伐替尼、程序性死亡-1抑制剂及碘-125粒子近距离放疗治疗门静脉癌栓型肝细胞癌的疗效及安全性
Brachytherapy. 2023 Nov-Dec;22(6):858-871. doi: 10.1016/j.brachy.2023.06.229. Epub 2023 Aug 12.
9
Effectiveness of transarterial chemoembolization in combination with lenvatinib and programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.经动脉化疗栓塞联合乐伐替尼及程序性细胞死亡蛋白1抑制治疗不可切除肝细胞癌的疗效
World J Gastrointest Oncol. 2024 Jul 15;16(7):2884-2887. doi: 10.4251/wjgo.v16.i7.2884.
10
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.仑伐替尼联合 PD-1 抑制剂与或不与经动脉化疗栓塞治疗不可切除肝细胞癌的疗效和安全性。
Hepatol Int. 2023 Jun;17(3):753-764. doi: 10.1007/s12072-023-10502-3. Epub 2023 Apr 10.

引用本文的文献

1
The Metazoan SpoT Homolog 1 promotes ferroptosis by regulating the intracellular redox cycle and iron levels in hepatocellular carcinoma.后生动物SpoT同源物1通过调节细胞内氧化还原循环和肝细胞癌中的铁水平来促进铁死亡。
Int J Clin Oncol. 2025 Jul 25. doi: 10.1007/s10147-025-02818-x.

本文引用的文献

1
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.经动脉化疗栓塞联合乐伐替尼加程序性细胞死亡蛋白-1抑制治疗不可切除肝细胞癌的疗效及预测因素
World J Gastrointest Oncol. 2024 Apr 15;16(4):1236-1247. doi: 10.4251/wjgo.v16.i4.1236.
2
Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.基于免疫特征的 TACE 联合仑伐替尼加 PD-1 抑制剂治疗伴有门静脉癌栓的肝细胞癌的相关性和疗效。
Cancer Med. 2023 May;12(10):11315-11333. doi: 10.1002/cam4.5841. Epub 2023 Mar 23.
3
Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.在中国真实世界中，乐伐替尼联合PD-1抑制剂加经动脉化疗栓塞术治疗不可切除肝细胞癌患者的疗效和安全性
Front Oncol. 2022 Jul 4;12:950266. doi: 10.3389/fonc.2022.950266. eCollection 2022.
4
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.肝细胞癌合并门静脉癌栓患者的管理：一篇叙述性综述。
Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):134-144. doi: 10.1016/j.hbpd.2021.12.004. Epub 2021 Dec 16.
5
Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma.乐伐替尼作为晚期肝细胞癌靶向治疗的概述。
Clin Exp Hepatol. 2021 Sep;7(3):249-257. doi: 10.5114/ceh.2021.109312. Epub 2021 Oct 11.
6
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma.原发性肝癌经动脉化疗栓塞术的最新进展。
Int J Mol Sci. 2020 Oct 31;21(21):8165. doi: 10.3390/ijms21218165.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.

不可切除的肝细胞癌：经动脉化疗栓塞联合乐伐替尼并联合程序性死亡-1抑制是一种可行的方法。

Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach.

作者信息

Zhao Fei-Yu, Wang Dong-Yu, Qian Nian-Song

机构信息

Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.

Department of Nephrology, General Hospital of the People's Liberation Army, Beijing 100853, China.

出版信息

World J Gastrointest Oncol. 2024 Oct 15;16(10):4042-4044. doi: 10.4251/wjgo.v16.i10.4042.

DOI:10.4251/wjgo.v16.i10.4042
PMID:39473949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11514670/
Abstract

In this editorial, we review the article "Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma". We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma. Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer, but the combination of all three therapeutic approaches needs more research.

摘要

在这篇社论中，我们回顾了《经动脉化疗栓塞联合乐伐替尼加程序性细胞死亡蛋白1抑制治疗不可切除肝细胞癌的疗效及预测因素》这篇文章。我们特别关注经动脉化疗栓塞联合乐伐替尼与程序性死亡1抑制剂联合使用是否可用于不可切除肝细胞癌患者。由于经动脉化疗栓塞以及乐伐替尼与程序性死亡1抑制剂联合使用在晚期肝癌治疗中都发挥着重要作用，但这三种治疗方法的联合应用还需要更多研究。